XLH: disease biology and the FGF23 axis

X-linked hypophosphatemia is the most prevalent heritable form of rickets, caused by inactivating mutations in the PHEX gene (phosphate-regulating endopeptidase homolog, X-linked) that result in chronic pathological overproduction of fibroblast growth factor 23 (FGF23). PHEX deficiency prevents normal degradation of FGF23 into inactive fragments, though the precise molecular mechanism remains incompletely elucidated in the literature. The downstream consequences are twofold: suppression of sodium-phosphate cotransporters NaPi2a (SLC34A1) and NaPi2c (SLC34A3) in renal proximal tubules — causing chronic phosphate wasting — and inhibition of renal 1α-hydroxylase, which reduces production of 1,25-dihydroxyvitamin D (calcitriol) and amplifies hypophosphatemia.

FGF23 is produced primarily by osteocytes and osteoblasts in bone. Its biological activity depends critically on the co-receptor α-Klotho, which is essential for high-affinity FGF23 binding to FGF receptors — particularly FGFR1 and FGFR3 — in the kidney. Beyond phosphate handling, FGF23 activates with-no-lysine kinase 4 (WNK4) in distal renal tubules, enhancing renal calcium and sodium reabsorption. This indicates phosphate-independent pleiotropic effects with potential cardiovascular implications, as documented by research from the University of Veterinary Medicine Vienna.

Research from Harvard Medical School further elaborates that elevated FGF23 in XLH impairs growth plate maturation, lacuno-canalicular remodeling in osteocytes, and enthesopathy development — broadening the disease target profile beyond renal phosphate handling to encompass systemic skeletal and dental manifestations. The PiT2/Slc20a2 sodium-phosphate cotransporter, identified by the University of Nantes, represents a potentially novel upstream regulatory node modulating phosphate-dependent FGF23 secretion in bone.

Burosumab clinical evidence: from Phase 1 to real-world use

Burosumab (KRN23; Crysvita®) — a fully human IgG1 monoclonal antibody that binds and neutralizes circulating FGF23 — is approved for children aged 1 year and older and for adults with XLH, representing the first therapy to directly target the primary pathological driver rather than manage downstream symptoms. The clinical evidence base spans Phase 1 through Phase 3/4 trials across adult and pediatric cohorts, multiple ethnic populations, and early real-world studies.

The pivotal adult evidence comes from a randomized, double-blind, placebo-controlled Phase 3 trial conducted at Duke University Medical Center (2018). The trial demonstrated that burosumab 1 mg/kg subcutaneously corrected hypophosphatemia, improved pseudofracture healing, reduced pain and stiffness, and improved physical functioning in symptomatic adults with XLH over 24 weeks. In children, a Phase 3/4 open-label trial conducted at four Japanese medical centers by Kyowa Kirin (2022) enrolled 15 children aged 1–12 years and followed them for up to 124 weeks. Burosumab was initiated at 0.8 mg/kg every two weeks and titrated to a maximum of 2 mg/kg; the trial demonstrated normalization of serum phosphorus, improvement in rickets severity scores, and improvement in motor function and growth velocity.

“A population PK/PD analysis by Certara (2021) incorporated 2,844 burosumab serum concentrations from 277 subjects across 9 clinical studies — characterizing first-order subcutaneous absorption, one-compartment distribution, and linear elimination kinetics.”

Ethnic population data comes from a Phase 1 first-in-Asian study at Osaka University (2018), which established safety, pharmacokinetics, and pharmacodynamic proof-of-concept in Japanese and Korean adults. Real-world evidence generation is progressing: an Israeli observational study (2021) examined body composition, blood pressure, and cardiometabolic parameters in growing children on burosumab, while a prospective case-control study from Tel Aviv (2022) assessed dental health outcomes in ten children with XLH after three years of burosumab therapy, documenting improvement in height z-score and dental parameters at year 1.

The prior standard of care — multiple daily oral doses of inorganic phosphate combined with active vitamin D analogues (calcitriol or alfacalcidol) — is consistently described in the retrieved literature as inadequate. Tokyo Metropolitan Children’s Medical Center (2022) notes that adult height on conventional therapy often remains below −2 SD. Documented risks include gastrointestinal intolerance, nephrocalcinosis, hypercalciuria, and secondary or tertiary hyperparathyroidism. These limitations position conventional therapy as a historical comparator rather than a development target, according to EMA-recognized clinical guidelines and multiple retrieved review papers.

Label expansion beyond XLH is supported by case report evidence. Retrieved results include burosumab use in cutaneous skeletal hypophosphatemia syndrome (CSHS) — a condition caused by somatic RAS gain-of-function mutations with FGF23-mediated hypophosphatemia — with a long-term follow-up from Leipzig (2022, 42 months) demonstrating phosphate normalization, growth improvement, and reduction in rickets severity.

Patent landscape: dosing optimization and indication expansion

The commercial patent estate around anti-FGF23 therapy is concentrated in a focused cluster of filings from Kyowa Kirin Co., Ltd. and Ultragenyx Pharmaceutical Inc., spanning US, AU, and EP jurisdictions. The core claims cover methods for administering anti-FGF23 pharmaceutical compositions to achieve “effective and efficient control of FGF23 activity” — defined by the relationship between serum phosphate levels and regulated FGF23 concentrations within a chronic dosing cycle.

A 2024 active Kyowa Kirin US patent extends claims to increasing bone remodeling markers including P1NP, CTX, osteocalcin, and BALP as endpoints of anti-FGF23 treatment — signaling a move toward biomarker-guided dosing as a differentiating IP strategy. A further EP filing dated 2025 remains pending, indicating ongoing prosecution activity. The Ultragenyx EP patents (filed 2017, granted 2020) suggest a co-development or licensing relationship with the burosumab IP estate, as documented by EPO records.

For developers of next-generation anti-FGF23 biologics or biosimilars, navigating this dosing method IP estate will be essential — particularly given the active pending EP filing dated 2025. The small molecule FGF23 inhibitor program at the University of Tennessee represents a potentially distinct IP space, as oral small molecules may avoid the method-of-administration claims covering subcutaneous anti-FGF23 antibody dosing. According to WIPO patent classification frameworks, method-of-treatment claims in rare disease biologics have increasingly become a primary competitive battleground.

Emerging modalities: small molecules, PHEX mimetics, and osteocyte targets

Beyond the approved anti-FGF23 antibody, the XLH pipeline contains several mechanistically distinct modalities at preclinical stages — each targeting different nodes in the FGF23 regulatory network and representing differentiated opportunities for the next wave of drug development.

Small molecule FGF23 antagonists

Researchers at the University of Tennessee (2020) identified ZINC13407541 (N-[[2-(2-phenylethenyl)cyclopenten-1-yl]methylidene]hydroxylamine) as a small molecule FGF23 antagonist that directly binds FGF23 and prevents activation of FGFR/α-Klotho complexes. Structure-activity relationship (SAR) studies generated analogues with improved drug-like properties. In vivo studies in Hyp mice — the murine XLH homologue — demonstrated increased serum phosphate and improvement in skeletal abnormalities. Small molecule inhibitors may offer pharmacokinetic and manufacturing advantages over systemically administered antibodies, and may be particularly relevant in resource-limited settings or for patients with compliance challenges with subcutaneous injection.

PHEX pathway mimetics (SPR4-peptide)

A 4.2 kDa synthetic peptide — the SPR4-peptide — was described by the University of Tennessee Health Science Center (2014) as a PHEX mimetic that binds ASARM-peptides/motifs to modulate the PHEX-DMP1-integrin complex and partially suppress FGF23 expression. In Hyp mice, subcutaneous infusion via osmotic pump partially corrected hypophosphatemia and increased serum 1,25(OH)₂D₃, though serum FGF23 remained elevated. This approach targets an upstream node in the bone mineralization regulatory network rather than FGF23 directly, and remains at the preclinical stage.

Osteocyte FGFR1 as a druggable upstream target

Research from Tokushima University (2021) and the University of Tennessee (2014) demonstrates that conditional osteocyte-specific FGFR1 deletion in Hyp mice produces a 70% decrease in bone Fgfr1 transcripts, a 50% reduction in FGF23 bone expression, and a 3-fold reduction in serum FGF23. A separate finding from Tokushima University shows that osteocyte-specific FGFR1 knockout reduces serum phosphate by disrupting GALNT3-mediated regulation of FGF23 production. These results identify autocrine/paracrine FGFR1 signaling in osteocytes as a potential druggable target for reducing FGF23 production at source — complementary to circulating FGF23 neutralization by burosumab.

PTEN/AKT/mTORC1 intracellular pathway modulation

A paper from Osaka Women’s and Children’s Hospital (2020) demonstrates that osteocyte-specific PTEN knockout mice exhibit decreased intact FGF23 via AKT/mTORC1 activation, revealing a new intracellular signaling axis regulating FGF23 production in osteocytes. Although entirely preclinical, this pathway represents a novel target concept for reducing excessive FGF23 production at its cellular origin. No clinical data for any of these three preclinical modalities are available in the retrieved dataset.

Combination strategies and next-generation pipeline signals

Burosumab monotherapy may be insufficient in a subset of XLH patients — specifically those with complicating tertiary hyperparathyroidism — and emerging research is identifying additional residual disease mechanisms that combination approaches could address.

Burosumab + calcimimetic for tertiary hyperparathyroidism

A case report from Fukuoka University School of Medicine (2022) describes an adult XLH patient with tertiary hyperparathyroidism in whom burosumab monotherapy was insufficient to normalize TmP/GFR. Addition of the calcimimetic evocalcet — targeting PTH-driven phosphaturia — restored phosphate reabsorption. This signals a potential combination rationale for a subset of adult XLH patients with residual PTH-driven phosphaturia that is not addressed by FGF23 neutralization alone.

Addressing local mineralization inhibitors

Spatial metabolomics research from the University of Veterinary Medicine Vienna (2022) applied MALDI-FTICR mass spectrometry imaging to undecalcified bone cryosections of Hyp mice, revealing upregulation of pyrophosphate-producing pathways in cortical bone. This suggests that local accumulation of mineralization inhibitors — beyond systemic hypophosphatemia — contributes to the XLH bone phenotype, and may identify new targets for combination with anti-FGF23 therapy to address residual mineralization defects not corrected by phosphate normalization alone.

Long-term safety surveillance as a pipeline consideration

Multiple retrieved review papers flag that long-term nephrocalcinosis risk, cardiac calcification, and growth plate effects of anti-FGF23 antibody therapy have not been fully characterized. FGF23’s activation of WNK4 in distal renal tubules — enhancing calcium and sodium reabsorption — indicates pleiotropic cardiovascular effects that warrant monitoring. Developers and clinical investigators should anticipate post-marketing commitments and monitor real-world evidence registries for these endpoints, which may affect pediatric label maintenance and adult dosing guidelines, as referenced in frameworks published by the FDA for rare disease biologics.

The strategic picture that emerges from the retrieved evidence is one of a platform indication: XLH approval has established the regulatory and clinical proof-of-concept for anti-FGF23 therapy, with patent claims already extending to six related FGF23-excess disorders. The preclinical pipeline — small molecule antagonists, osteocyte-targeted approaches, and combination hypotheses — represents the next generation of differentiation opportunities in a field where the primary IP barrier is not the antibody itself but the dosing method and biomarker-guided administration claims held by Kyowa Kirin and Ultragenyx. Researchers and developers seeking to map this landscape further can access the full patent and literature dataset via PatSnap Eureka‘s AI-powered drug pipeline intelligence platform.